Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""de Weger, Vincent A"" wg kryterium: Autor


Wyświetlanie 1-16 z 16
Tytuł:
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
Autorzy:
van Eijk, MaartenAff1, IDs0028002204445z_cor1
Yu, Huixin
Sawicki, EmiliaAff1, Aff2
de Weger, Vincent A.
Nuijen, Bastiaan
Dorlo, Thomas P. C.
Beijnen, Jos H.Aff1, Aff4
Huitema, Alwin D. R.Aff1, Aff5, Aff6
Pokaż więcej
Źródło:
Cancer Chemotherapy and Pharmacology. 90(1):71-82
Czasopismo naukowe
Tytuł:
Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours
Autorzy:
Vermunt, Marit A. C.
van der Heijden, Lisa T.
Hendrikx, Jeroen J. M. A.Aff1, Aff2
Schinkel, Alfred H.
de Weger, Vincent A.
van der Putten, Eric
van Triest, Baukelien
Bergman, Andries M.
Beijnen, Jos H.Aff1, Aff3, Aff6
Pokaż więcej
Źródło:
Cancer Chemotherapy and Pharmacology. 87(6):855-869
Czasopismo naukowe
Tytuł:
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours
Autorzy:
Vermunt, Marit A. C.
de Weger, Vincent A.
Janssen, Julie M.
Lopez-Yurda, Marta I.
Keessen, Marianne
Thijssen, Bas
Rosing, Hilde
Huitema, Alwin D. R.Aff1, Aff4
Beijnen, Jos H.Aff1, Aff3, Aff5
Marchetti, Serena
Pokaż więcej
Źródło:
Drugs in R&D. 21(1):103-111
Czasopismo naukowe
Tytuł:
Quantification of the pharmacokinetic-toxicodynamic relationship of oral docetaxel co-administered with ritonavir
Autorzy:
Yu, Huixin
Janssen, Julie M.
de Weger, Vincent A.
Nuijen, Bastiaan
Stuurman, Rik E.Aff1, Aff3
Marchetti, Serena
Schellens, Jan H. M.Aff2, Aff4, Aff5
Beijnen, Jos H.Aff1, Aff4, Aff5
Dorlo, Thomas P. C.
Huitema, Alwin D. R.Aff1, Aff6
Pokaż więcej
Źródło:
Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 38(5):1526-1532
Czasopismo naukowe
Tytuł:
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
Autorzy:
de Weger, Vincent A.
Stuurman, Frederik E.
Hendrikx, Jeroen J.M.A.
Moes, Johannes J.
Sawicki, Emilia
Huitema, Alwin D.R.
Nuijen, Bastiaan
Thijssen, Bas
Rosing, Hilde
Keessen, Marianne
Mergui-Roelvink, Marja
Beijnen, Jos H.
Schellens, Jan H.M.
Marchetti, Serena
Pokaż więcej
Źródło:
In European Journal of Cancer November 2017 86:217-225
Czasopismo naukowe
Tytuł:
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
Autorzy:
Gluck, W. Larry
Gounder, Mrinal M.
Frank, Richard
Eskens, Ferry
Blay, Jean Yves
Cassier, Philippe A.
Soria, Jean-CharlesAff6, Aff7
Chawla, Sant
de Weger, Vincent
Wagner, Andrew J.
Siegel, David
De Vos, Filip
Rasmussen, Erik
Henary, Haby A.
Pokaż więcej
Źródło:
Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 38(3):831-843
Czasopismo naukowe
Tytuł:
A Population Pharmacokinetic Model of Oral Docetaxel Coadministered With Ritonavir to Support Early Clinical Development.
Autorzy:
Yu, Huixin
Janssen, Julie M.
Sawicki, Emilia
van Hasselt, J. G. Coen
de Weger, Vincent A.
Nuijen, Bastiaan
Schellens, Jan H. M.
Beijnen, Jos H.
Huitema, Alwin D. R.
Pokaż więcej
Temat:
COMBINATION drug therapy
INTRAVENOUS therapy
LIVER
ORAL drug administration
DRUG tablets
DOCETAXEL
DRUG development
RITONAVIR
Źródło:
Journal of Clinical Pharmacology; Mar2020, Vol. 60 Issue 3, p340-350, 11p
Czasopismo naukowe
Tytuł:
A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.
Autorzy:
de Weger VA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Vermunt MAC; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Stuurman FE; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Burylo AM; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Damoiseaux D; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Hendrikx JJMA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sawicki E; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.
Moes JJ; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, The Netherlands.
Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mergui-Roelvink M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Źródło:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Jun; Vol. 10 (6), pp. 607-621. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Neoplasms/*drug therapy
Administration, Oral ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Paclitaxel/administration & dosage ; Ritonavir/administration & dosage
Czasopismo naukowe
    Wyświetlanie 1-16 z 16

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies